NCT05093036

Brief Summary

Offering PrEP care online and reducing the frequency of monitoring may increase access to HIV PrEP. The objective of this study is to assess the non-inferiority of an internet-based HIV PrEP-service and reduced frequency of monitoring visits in comparison to standard-of-care at the Public Health Service in 4 regions in the Netherlands: Amsterdam, Rotterdam-Rijnmond, Haagland and Gelderland-Zuid.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
469

participants targeted

Target at P50-P75 for not_applicable hiv-infections

Timeline
Completed

Started Sep 2021

Typical duration for not_applicable hiv-infections

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 21, 2021

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

October 13, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

October 26, 2021

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2024

Completed
Last Updated

December 13, 2024

Status Verified

December 1, 2024

Enrollment Period

2.5 years

First QC Date

October 13, 2021

Last Update Submit

December 10, 2024

Conditions

Keywords

Pre-Exposure Prophylaxis (PrEP)PreventionE-Health

Outcome Measures

Primary Outcomes (1)

  • Adherence to PrEP regimen

    Non-adherence is defined as a PrEP-less and condom-less anal sex act with a casual partner, termed an unprotected act (UA). Self-reported daily data on sexual behaviour, pill intake and condom use are recorded in an electronic diary. Using these data, we will count the number of UAs (n), and the person-months at risk (pmar) per person; this will yield the incidence rate (IR) per person month (= n / pmar). This will be done for each study arm separately.

    18 months for each individual study participant

Study Arms (4)

Arm 1: routine PrEP care at the CSH, monitoring 4 times per year (standard-of-care)

NO INTERVENTION

Study participants in arm 1 follow routine care procedures, i.e. the number of monitoring visits is four times a year. * Experienced PrEP users: first monitoring visit is three months after the enrolment into the study. * PrEP-naïve participants: first monitoring visit is one month after enrolment in the study and start of PrEP use. The second monitoring visit is 2 months after the first monitoring contact (3 months after enrolment).

Arm 2: routine PrEP care at the CSH, monitoring 2 times per year

EXPERIMENTAL

Study participants in arm 2 follow routine care procedures but with a reduced frequency of monitoring visits, i.e. the number of monitoring visits is reduced from four to two times a year. Timing of the first monitoring visit differs per PrEP user type: * Experienced PrEP users: first monitoring visit is six months after the enrolment into the study. * PrEP-naïve participants: first monitoring visit is one month after enrolment in the study and start of PrEP use. The second monitoring visit is five months after the first monitoring visit (6 months after enrolment).

Other: Variations in PrEP care delivery at public health services

Arm 3: online PrEP care, monitoring 4 times per year

EXPERIMENTAL

Study participants in arm 3 receive internet-based PrEP care, i.e. video consultations and online-mediated testing for HIV, STIs and renal function, online PrEP ordering and (at home) delivery of PrEP. Monitoring occurs four times per year. * Experienced PrEP users: first monitoring contact is three months after the enrolment into the study. * PrEP-naïve participants: first monitoring contact is one month after enrolment in the study and start of PrEP use. The second monitoring visit is 2 months after the first monitoring contact (3 months after enrolment).

Other: Variations in PrEP care delivery at public health services

Arm 4: online PrEP care, monitoring 2 times per year

EXPERIMENTAL

Study participants in arm 4 receive internet-based PrEP care, i.e. video consultations and online-mediated testing for HIV, STIs and renal function, online PrEP ordering and (at home) delivery of PrEP. Monitoring occurs two times per year. * Experienced PrEP users: first monitoring contact is six months after the enrolment into the study. * PrEP-naïve participants: first monitoring contact is one month after enrolment in the study and start of PrEP use. The second monitoring visit is five months after the first monitoring contact (6 months after enrolment).

Other: Variations in PrEP care delivery at public health services

Interventions

Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring

Arm 2: routine PrEP care at the CSH, monitoring 2 times per yearArm 3: online PrEP care, monitoring 4 times per yearArm 4: online PrEP care, monitoring 2 times per year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 18 years or older;
  • Meeting the eligibility criteria of the NPP i.e. being a MSM or transgender persons who in the 6 months prior to the PrEP-request/PrEP-consultation:
  • Had anal sexual intercourse without a condom with a male partner with an un-known HIV status, and/or;
  • Had anal sexual intercourse without a condom with a male partner with a known HIV-positive status and a detectable viral load, and/or;
  • Was diagnosed with a rectal STI, and/or;
  • Received a prescription for post-exposure prophylaxes (PEP);
  • Living in the catchment area of one of the participating GGD regions;
  • Having a smartphone, internet access and email address;
  • Sufficient understanding of Dutch or English; and
  • Signed informed consent.

You may not qualify if:

  • HIV infection;
  • Chronic or acute Hepatitis B virus infection;
  • Diminishing renal function:
  • eGFR less than 60 mL/min/1.73m2;
  • Other renal problems, as diagnosed by a physician and advised against using TFV;
  • Chronic use of medication that interacts with TFV/FTC e.g. NSAIDs.
  • Other medical conditions that require special attention when using PrEP, such as osteoporosis or other bone diseases;
  • Unlikely, in the opinion of the clinician, to comply with the study requirements or procedures;
  • Participating in another study that affects the primary or secondary outcome measures of our study;
  • Investigators or otherwise dependent persons.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Public Health Service of Amsterdam

Amsterdam, 1018 WT, Netherlands

Location

Public Health Service Gelderland-Zuid

Nijmegen, Netherlands

Location

Public Health Service Rotterdam-Rijnmond

Rotterdam, Netherlands

Location

Public Health Service Haaglanden

The Hague, Netherlands

Location

Related Publications (1)

  • Groot Bruinderink ML, Boyd A, Coyer L, Boers S, Blitz L, Brand JM, Gotz HM, Stip M, Woudstra J, Yap K, Vermey K, Matser A, Feddes AR, Jongen VW, Prins M, Hoornenborg E, van Harreveld F, Schim van der Loeff MF, Davidovich U. Online-Mediated HIV Pre-exposure Prophylaxis Care and Reduced Monitoring Frequency for Men Who Have Sex With Men: Protocol for a Randomized Controlled Noninferiority Trial (EZI-PrEP Study). JMIR Res Protoc. 2023 Nov 8;12:e51023. doi: 10.2196/51023.

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Officials

  • Udi Davidovich, PhD

    Public Health Service of Amsterdam

    PRINCIPAL INVESTIGATOR
  • Maarten Schim van der Loeff

    Public Health Service of Amsterdam

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: We will implement a multi-center, four-arm, non-inferiority randomised controlled trial to evaluate online PrEP care and/or a reduced schedule of monitoring visits against routine (face-to-face) PrEP care at the Centers of Sexual Health (CSH) of the Public Health Services (PHS) (standard-of-care). After eligibility screening and assessment, study participants are randomized (1:1:1:1) to the standard-of-care arm (i.e. location: CSH; 4 annual monitoring visits) or one of three interventions arms: arm 2 (location: CSH; 2 annual monitoring visit), arm 3 (location: online; 4 annual monitoring visits), arm 4 (location: online; 2 annual monitoring visits). In the randomization process, participants will be stratified based on PrEP experience (PrEP-naïve or experienced) and PHS catchment area (4 regions). In each arm, we aim to include at least 25% PrEP-naïve participants.
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior researcher (PhD)

Study Record Dates

First Submitted

October 13, 2021

First Posted

October 26, 2021

Study Start

September 21, 2021

Primary Completion

March 31, 2024

Study Completion

September 30, 2024

Last Updated

December 13, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations